Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
Oncolys BioPharma plans to initiate a PII study of its oncolytic virus telomelysin in Japan in the second half of 2019 to obtain data for regulatory approval for an indication of esophageal cancer, President Yasuo Urata told Jiho, indicating its…
To read the full story
Related Article
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Shionogi Highlights ViiV’s Long-Term HIV IP Strategy
August 4, 2026
- Kyowa Kirin Profits Surge as R&D Costs Fall, Overseas Sales Grow
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…